Exercise News and Research

Latest Exercise News and Research

Amarin reports $31.4 million cash balance for third quarter 2010

Amarin Corporation plc, a clinical-stage biopharmaceutical company focused on cardiovascular disease, today reported its financial and operational results for the three-month period ended September 30, 2010.

10 Nov 2010

Exact Sciences completes underwritten public offering

Exact Sciences Corp. today announced that it has completed its previously announced underwritten public offering of common stock at a price of $6.00 per share.

10 Nov 2010

Cerus prices underwritten public offering

Cerus Corporation today announced the pricing of an underwritten public offering of 7,368,422 units, with each unit consisting of one share of its common stock and a warrant to purchase 0.5 of a share of its common stock, at a price to the public of $2.85 per unit. The aggregate public offering price of this offering is approximately $21.0 million, and the net proceeds to the Company, after deducting underwriting discounts and commissions, but before legal and other estimated offering expenses, are expected to be approximately $19.7 million.

10 Nov 2010

Experts to discuss public health issues on using mobile health technology at 2010 mHealth Summit

As obesity rates and the cost of healthcare continue to be on the rise, the 2010 mHealth Summit in Washington D.C. is bringing together industry thought leaders, researchers, and policy makers to discuss the opportunities to address pressing public health issues utilizing mobile health technology.

10 Nov 2010

Physical activity lowers risk of endometrial cancer

Women who exercise for 150 minutes a week or more may see a reduced risk of endometrial cancer, despite whether or not they are overweight, according to data presented at the Ninth Annual AACR Frontiers in Cancer Prevention Research Conference, held here Nov. 7-10, 2010.

10 Nov 2010

Discovery Labs reports net operating loss of $6.2 million for third quarter 2010

Discovery Laboratories, Inc., a biotechnology company developing its novel, synthetic, peptide-containing surfactant and related aerosolization technologies as first in class therapies for severe respiratory diseases, today provides an update on key pipeline and business initiatives and a financial update for the third quarter ended September 30, 2010.

9 Nov 2010

American Specialty Health wins Silver California Fit Business Award for fourth time

Health and wellness company American Specialty Health Incorporated (ASH) announced that it had received a Silver California Fit Business Award for the fourth time from the California Task Force on Youth and Workplace Wellness.

9 Nov 2010

Study demonstrates preventive effect of urate lowering therapy on cardiovascular mortality

The use of urate lowering therapy might successfully prevent death from cardiovascular disease in people with gout, according to research presented at the Nov 2010, American College of Rheumatology Annual Scientific Meeting in Atlanta.

9 Nov 2010

Angiotech reports $59.0 million total revenue for third quarter 2010

Angiotech Pharmaceuticals, Inc. today announced that it had released its financial results for the third quarter ended September 30, 2010.

9 Nov 2010

Arena and Eisai report positive results from lorcaserin BLOOM-DM trial in obese, overweight diabetics

Arena Pharmaceuticals, Inc. and Eisai Inc. reported today that top-line results from the one-year lorcaserin BLOOM-DM trial demonstrate statistically significant weight loss in obese and overweight patients with type 2 diabetes. In this trial, lorcaserin met all three co-primary efficacy endpoints. In addition, as described below, lorcaserin patients taking lorcaserin 10 mg twice daily (BID) achieved statistically significant improvements in multiple secondary endpoints, including HbA1c, as compared to patients randomized to placebo.

9 Nov 2010

Interleukin Genetics receives two grants under QTDP program to advance obesity, osteoarthritis genetic research

Interleukin Genetics, Inc. today announced that on November 1, 2010 notification was received that it has been awarded two grants totaling $473,393 by the United States Government under the Qualifying Therapeutic Discovery Project (QTDP) Program to advance the Company's genetic research projects related to obesity and osteoarthritis.

9 Nov 2010

EpiCept third quarter net loss decreases to $3.2 million

EpiCept Corporation today announced operating and financial results for the three and nine months ended September 30, 2010, and provided an update with respect to the Company's key business initiatives.

9 Nov 2010

Duke focuses on community health in N.C.; Baltimore mental health agency's practices raise questions; Mass. clinic’s efforts to curb diabetes highlighted

The Washington Post reports on Duke University's experiment with community health centers Duke University has been focusing closer attention on the neighborhood that surrounds it by forming a partnership with Durham's Federally Qualified Health Center.

9 Nov 2010

TechniScan restructures convertible debt

TechniScan, Inc. a medical device company engaged in the development and commercialization of an automated breast ultrasound imaging system, today announced a restructuring of its convertible debt.

8 Nov 2010

Thirteen myths about arthritis and rheumatic disease

A diagnosis of arthritis or another rheumatic disease can cause someone to feel anxious and even a little overwhelmed. Being a knowledgeable and empowered patient can help alleviate some of those feelings, and being able to navigate through the many misconceptions about arthritis and rheumatic diseases is vitally important.

8 Nov 2010

Santarus's budesonide MMX drug shows positive result for active ulcerative colitis

Santarus, Inc. a specialty biopharmaceutical company, today announced positive top-line results from a second Phase III clinical study evaluating the safety and efficacy of budesonide MMX for the induction of remission of mild or moderate active ulcerative colitis.

8 Nov 2010

EpiCept to receive $1.9 million in net proceeds

EpiCept Corporation announced today that it has entered into definitive agreements for the purchase of approximately 3.3 million shares of its common stock at $0.61 per share, and five-year warrants to purchase up to approximately 1.3 million shares of common stock at an exercise price of $0.56 per share, exercisable immediately.

8 Nov 2010

Fast food restaurants to display calorie counts

As Australia reels under the weight of obesity and related diseases one of the first steps towards prevention could be forcing fast food restaurants to display kilojoule counts on their menus said NSW Premier Kristina Keneally.

7 Nov 2010

Omeros third quarter net loss increases to $7.6 million

Omeros Corporation, a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system, today announced its financial results for the third quarter of 2010.

4 Nov 2010

Testosterone treatment for frailty in older men lacks long term benefits

The beneficial effects of six months of testosterone treatment on muscle mass, strength and quality of life in frail elderly men are not maintained at six months post-treatment, according to a study accepted for publication in The Endocrine Society's Journal of Clinical Endocrinology & Metabolism (JCEM).

4 Nov 2010

Exercise News and Research

Latest Exercise News and Research

Amarin reports $31.4 million cash balance for third quarter 2010

Exact Sciences completes underwritten public offering

Cerus prices underwritten public offering

Experts to discuss public health issues on using mobile health technology at 2010 mHealth Summit

Physical activity lowers risk of endometrial cancer

Discovery Labs reports net operating loss of $6.2 million for third quarter 2010

American Specialty Health wins Silver California Fit Business Award for fourth time

Study demonstrates preventive effect of urate lowering therapy on cardiovascular mortality

Angiotech reports $59.0 million total revenue for third quarter 2010

Arena and Eisai report positive results from lorcaserin BLOOM-DM trial in obese, overweight diabetics

Interleukin Genetics receives two grants under QTDP program to advance obesity, osteoarthritis genetic research

EpiCept third quarter net loss decreases to $3.2 million

Duke focuses on community health in N.C.; Baltimore mental health agency's practices raise questions; Mass. clinic’s efforts to curb diabetes highlighted

TechniScan restructures convertible debt

Thirteen myths about arthritis and rheumatic disease

Santarus's budesonide MMX drug shows positive result for active ulcerative colitis

EpiCept to receive $1.9 million in net proceeds

Fast food restaurants to display calorie counts

Omeros third quarter net loss increases to $7.6 million

Testosterone treatment for frailty in older men lacks long term benefits

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Exercise News and Research

Latest Exercise News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in